Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis.
Learn more about Sotyktu – Summary of Product Characteristics.
Experts from across five continents discuss regional biosimilar uptake and practical strategies for optimizing psoriasis treatment in this IPC-led symposium at ICD 2025 in Rome.
Oruka has joined the International Psoriasis Council as a 2025 Bronze Level Corporate Member, bringing its best-in-class monoclonal antibody therapies to advance psoriasis and psoriatic arthritis research and patient care.
Join IPC in welcoming Alumis Inc. as a 2024 Bronze Level Corporate Member! Discover how Alumis’ innovative research and dedication to patient care support IPC’s global mission to enhance and improve psoriasis treatment.
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.
